Experimental antibody for severe COVID-19 falls short as trial ends early
Disease control
Terminated
This study tested an experimental antibody called SCTA01 in hospitalized adults with severe COVID-19. The goal was to see if it could speed up recovery compared to a placebo. The trial was stopped early after enrolling 102 participants, so the results are limited.
Phase: PHASE2, PHASE3 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC